Safety and Efficacy of the Use of Botox on Acne


• To determine the safety and efficacy of Botox Treatment in subjects with mild to moderate acne vulgaris defined by the Investigator's Global Assessment (IGA)

Full Title of Study: “Double-Blind, Randomized, Placebo-Controlled Study to Determine the Safety and the Efficacy of Using Botulinum Neurotoxin Type A Injections for Subjects With Mild to Moderate Acne Vulgaris”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Outcomes Assessor)
  • Study Primary Completion Date: December 2008

Detailed Description

• 90 day trial, with botox being injected at baseline/screening visit. Photos will be taken throughout the study and patients will be evaluated by masked injector evaluator and a masked evaluator. Patient will complete a subject evaluation at each visit. Follow-up visits occur at Day 3, 7, 14, 30 and 90.


  • Drug: Botulinum Neurotoxin Type A
    • 1.5-3 units of Botox/lesion
  • Drug: Bacteriostatic saline
    • .1 cc bacteriostatic saline/lesion

Arms, Groups and Cohorts

  • Experimental: Botox and Placebo on each side of face
    • Botulinum Neurotoxin Type A (Botox, 1.5-3 units/lesion); Bacteriostatic saline solution (0.11 cc/lesion)

Clinical Trial Outcome Measures

Primary Measures

  • Change in Mean Lesion Count From Baseline at 90 Days
    • Time Frame: Baseline and 90 days
    • To determine the safety and efficacy of Botox Treatment in subjects with mild to moderate acne vulgaris defined by the Investigator’s Global Assessment (IGA)

Participating in This Clinical Trial

Inclusion Criteria

  • Between the age of 18 and 50 years of age – Not pregnant and negative pregnancy test, not planning on getting pregnant – Mild to moderate bilateral acne lesions on the face – Able to understand the requirements of the study and sign an Informed Consent Form – Have the time and ability to complete the study and comply with instructions(i.e will be around for the duration of the study) – Skin types I, II, III, IV and V Exclusion Criteria:

  • Subject has skin type VI – Subject has a significant concurrent illness, such as diabetes, epilepsy, lupus or congestive heart disease – Concurrent skin conditions affecting area to be treated – Prior exposure to any serotype of botulinum toxin for any purpose in the 3 months immediately prior to study enrollment – Prior surgery on the area to be treated within 3 months of initial treatment or during this clinical evaluation – Open laceration, abrasion active cold sores or herpes sores, multiple dysplastic nevi in areas to be treated? – Permanent or semi-permanent dermal filler treatment within the last 6 months – Medium or deep depth chemical peel resurfacing procedure within 3 months of treatment or during this clinical evaluation – Has used oral isotretinoin (Accutane) within 6 months, or use of topical isotretinoin within 3 months, of initial treatment or during this clinical evaluation – Prior light /laser treatments at target locations within 3 months of enrollment or during the course of this clinical evaluation – Any physical or mental condition which, in the investigator's opinion would make it unsafe for the subject to participate in the clinical evaluation – Use of oral antibiotics for acne and/or medication that cause photosensitivity within 2 weeks of initial treatment – Participation in a study of another investigational devices or drugs within 3 months of enrollment – Subject shows symptoms of a hormonal disorder – Subject cannot be treated for (past or present) any form of treatment of active cancer or having a history of skin cancer or any other cancer in the area to be treated – Subject is currently using immunosuppressive medications

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 50 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • DeNova Research
  • Provider of Information About this Clinical Study
    • Principal Investigator: Steven H. Dayan, Medical Director – DeNova Research
  • Overall Official(s)
    • Steven H Dayan, MD F.A.C.S., Principal Investigator, DeNova Research

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.